Immunogenicity and efficacy of the COVID-19 candidate vector vaccine MVA-SARS-2-S in preclinical vaccination

Severe acute respiratory syndrome (SARS) coronavirus 2 (SARS-CoV-2) has emerged as the infectious agent causing the pandemic coronavirus disease 2019 (COVID-19) with dramatic consequences for global human health and economics. Previously, we reached clinical evaluation with our vector vaccine based...

Descripción completa

Detalles Bibliográficos
Autores principales: Tscherne, Alina, Schwarz, Jan Hendrik, Rohde, Cornelius, Kupke, Alexandra, Kalodimou, Georgia, Limpinsel, Leonard, Okba, Nisreen M. A., Bošnjak, Berislav, Sandrock, Inga, Odak, Ivan, Halwe, Sandro, Sauerhering, Lucie, Brosinski, Katrin, Liangliang, Nan, Duell, Elke, Jany, Sylvia, Freudenstein, Astrid, Schmidt, Jörg, Werner, Anke, Gellhorn Serra, Michelle, Klüver, Michael, Guggemos, Wolfgang, Seilmaier, Michael, Wendtner, Clemens-Martin, Förster, Reinhold, Haagmans, Bart L., Becker, Stephan, Sutter, Gerd, Volz, Asisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: National Academy of Sciences 2021
Materias:
Biological Sciences
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8285915/
https://www.ncbi.nlm.nih.gov/pubmed/34162739
http://dx.doi.org/10.1073/pnas.2026207118

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8285915/
https://www.ncbi.nlm.nih.gov/pubmed/34162739
http://dx.doi.org/10.1073/pnas.2026207118

Ejemplares similares